PRIA Logo™
MarylandSB 03572025 Regular SessionSenate

Prescription Drug Affordability Board - Authority and Stakeholder Council Membership (Lowering Prescription Drug Costs for All Marylanders Now Act)

Sponsored By: Dawn Gile (Democratic)

Signed by Governor

Public HealthHealth - InsuranceCommerce and Business -see also- ElectrComm; ForeignTr; etc.Committees and CommissionsConsumer ProtectionDrugs -see also- Cannabis; ControlDangSubst; Pharm; etc.Fees -see also- Attys' Fees; Devt Fees & TaxesHealth -see also- COVID19; EnvHlth; MedCon; etc.Industry and TechnologyMedical AssistanceNoticesPrices -see also- Consumer Price IndexReimbursement RatesReportsRevenue and Taxes -see also- (specific tax)Sunset

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

3 provisions identified: 2 benefits, 0 costs, 1 mixed.

Maryland creates path toward drug payment limits

Maryland’s Prescription Drug Affordability Board must consult its Stakeholder Council and decide whether statewide drug payment limits serve Maryland’s best interest. If yes, it must create the process and set limits for drugs it finds cause or will cause affordability problems. Where applicable, it must consider government savings data, other states’ experience, and expected savings from Medicare’s negotiated maximum prices. The process excludes Medicare Part C and Part D reimbursements, federal 340B drug purchases, and federal payments Maryland cannot regulate. The law sets no specific payment limit or guaranteed household savings.

Medicaid drug limits require federal compliance review

Before setting a drug payment limit for Maryland Medicaid, the Board must consult the program. They must check for conflicts with Medicaid drug rebates, federal outpatient drug rules, and other federal requirements. They must also assess whether the limit requires more money for Medicaid’s budget. This review does not itself change Medicaid eligibility, drug coverage, or patient costs.

Drug payment limits include patient safeguards

The Board cannot apply a new payment limit to drugs listed in current shortage by the FDA or found scarce in Maryland. It may reconsider an existing limit if the drug becomes scarce. Pharmacy dispensing fees cannot count toward a drug payment limit or be capped by it. The Board must weigh effects on providers of 340B drugs and costs to administer, deliver, and handle drugs. For drugs designated for rare diseases or conditions, it must also consider effects on patients with rare diseases.

Sponsors & Cosponsors

Sponsor

  • Dawn Gile

    Democratic • Senate

Cosponsors

  • Brian J. Feldman

    Democratic • Senate

  • Katie Fry Hester

    Democratic • Senate

Roll Call Votes

All Roll Calls

Yes: 197 • No: 124

House vote • 4/7/2025

Third Reading Passed

Yes: 102 • No: 38

Senate vote • 4/7/2025

Third Reading Passed

Yes: 32 • No: 11 • Other: 1

Senate vote • 3/12/2025

Floor Amendment {823025/1 (Senator West) Rejected

Yes: 15 • No: 30 • Other: 2

Senate vote • 3/12/2025

Third Reading Passed

Yes: 35 • No: 12

Senate vote • 3/12/2025

Floor Amendment {223022/1 (Senator Ready) Rejected

Yes: 13 • No: 33 • Other: 1

Actions Timeline

  1. Approved by the Governor - Chapter 610

    5/20/2025

  2. Passed Enrolled

    4/7/2025Senate

  3. Third Reading Passed (32-11)

    4/7/2025Senate

  4. Senate Concurs House Amendments

    4/7/2025Senate

  5. Third Reading Passed (102-38)

    4/7/2025House

  6. Second Reading Passed with Amendments

    4/1/2025House

  7. Favorable with Amendments {873527/1 Adopted

    4/1/2025House

  8. Favorable with Amendments Report by Health and Government Operations

    4/1/2025House

  9. Hearing 3/27 at 1:00 p.m.

    3/15/2025House

  10. Referred Health and Government Operations

    3/13/2025House

  11. Third Reading Passed (35-12)

    3/12/2025Senate

  12. Second Reading Passed with Amendments

    3/12/2025Senate

  13. Floor Amendment {223022/1 (Senator Ready) Rejected (13-33)

    3/12/2025Senate

  14. Floor Amendment {823025/1 (Senator West) Rejected (15-30)

    3/12/2025Senate

  15. Floor Amendment {643725/1 (Senator West) Rejected

    3/12/2025Senate

  16. Committee Amendment {443427/1 Adopted

    3/12/2025Senate

  17. Motion Laid Over (Senator Salling) Adopted

    3/11/2025Senate

  18. Favorable with Amendments {443427/1

    3/11/2025Senate

  19. Favorable with Amendments Report by Finance

    3/10/2025Senate

  20. Hearing 2/06 at 1:00 p.m.

    1/22/2025Senate

  21. First Reading Finance

    1/16/2025Senate

Bill Text

  • Enacted

    5/20/2025

    PDF

  • Enrolled

    4/7/2025

    PDF

  • Third Reading

    3/12/2025

    PDF

  • First Reading

    1/16/2025

    PDF

Related Bills

Back to State Legislation